LEXICON PHARMACEUTICALS

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 dia... betes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

#SimilarOrganizations #People #Financial #Website #More

LEXICON PHARMACEUTICALS

Social Links:

Facebook

Twitter

Industry:

Bioinformatics Biotechnology Medical Pharmaceutical

Founded:

1995-01-01

Address:

The Woodlands, Texas, United States

Country:

United States

Website Url:

http://www.lexpharma.com

Total Employee:

251+

Status:

Active

Contact:

281-863-3000

Email Addresses:

[email protected]

Total Funding:

448.5 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Universal Analytics Domain Not Resolving Apache Microsoft Exchange Online

Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

Current Advisors List

not_available_image

Samuel L. Barker Board of Directors @ Lexicon Pharmaceuticals
Board_member
2000-03-01

judith-l-swain_image

Judith L. Swain Board of Directors @ Lexicon Pharmaceuticals
Board_member
2007-09-01

philippe-amouyal_image

Philippe Amouyal Board Member @ Lexicon Pharmaceuticals
Board_member
2007-08-01

not_available_image

Christopher Sobecki Chairman of the Board @ Lexicon Pharmaceuticals
Board_member

robert-lefkowitz_image

Robert Lefkowitz Member of the Board of Directors @ Lexicon Pharmaceuticals
Board_member
2001-02-01

frank-p-palantoni_image

Frank P. Palantoni Board of Directors @ Lexicon Pharmaceuticals
Board_member
2004-11-01

not_available_image

Alan S. Nies Board of Directors @ Lexicon Pharmaceuticals
Board_member
2003-11-01

frank-palantoni_image

Frank Palantoni Director, Board of Directors @ Lexicon Pharmaceuticals
Board_member
2004-09-01

Current Employees Featured

alan-j-main_image

Alan J. Main
Alan J. Main Executive Vice President of Pharmaceutical Research @ Lexicon Pharmaceuticals
Executive Vice President of Pharmaceutical Research
2007-02-01

brian-p-zambrowicz_image

Brian P. Zambrowicz
Brian P. Zambrowicz Executive Vice President and Chief Scientific Officer @ Lexicon Pharmaceuticals
Executive Vice President and Chief Scientific Officer
2007-02-01

pablo-lapuerta_image

Pablo Lapuerta
Pablo Lapuerta Executive Vice President of Clinical Development and Chief Medical Officer @ Lexicon Pharmaceuticals
Executive Vice President of Clinical Development and Chief Medical Officer
2013-03-01

james-f-tessmer_image

James F. Tessmer
James F. Tessmer Vice President of Finance and Accounting @ Lexicon Pharmaceuticals
Vice President of Finance and Accounting
2007-11-01

jeffrey-l-wade_image

Jeffrey L. Wade
Jeffrey L. Wade Executive Vice President and Chief Financial Officer @ Lexicon Pharmaceuticals
Executive Vice President and Chief Financial Officer
2010-05-01

brian-crum_image

Brian Crum
Brian Crum Vice President and General Counsel @ Lexicon Pharmaceuticals
Vice President and General Counsel

lonnel-coats_image

Lonnel Coats
Lonnel Coats President and CEO @ Lexicon Pharmaceuticals
President and CEO

Founder

allan-bradley_image

Allan Bradley

arthur-t-sands_image

Arthur T. Sands

Stock Details

Company's stock symbol is NASDAQ:LXRX

Acquisitions List

Date	Company	Article	Price
2001-06-13	Coelacanth	Coelacanth acquired by Lexicon Pharmaceuticals	32 M USD

Investors List

invus_image

Official Site Inspections

http://www.lexpharma.com Semrush global rank: 2.14 M Semrush visits lastest month: 9.37 K

Host Informations
Whois Informations

Loading ...